Vimarsana
Biggest News Aggregation in the World

Page 2 - Viswanathan Mohan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Viswanathan Mohan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Viswanathan Mohan Today - Breaking & Trending Today

Diabetes | India's diabetes burden much bigger than assumed, say researchers at MDRF - Vimarsana News

Diabetes | India's diabetes burden much bigger than assumed, say researchers at MDRF

An additional 136 million people nationwide also have prediabetes, a serious health condition marked by elevated blood sugar levels, among whom a large fraction are expected to advance into diabetes

Subramanian Ramadorai awarded Honorary Doctorate by Deakin University for his contributions to India's IT industry - Vimarsana News

Subramanian Ramadorai awarded Honorary Doctorate by Deakin University for his contributions to India's IT industry

New Delhi [India], February 17 (ANI/PRNewswire): Deakin University, Australia has recognised Subramanian Ramadorai for his distinguished lifetime achievement as a business leader, conferring upon him an honorary doctorate for his extensive contributions to the IT industry and his commitment to technological innovation for positive social outcomes.

According to a New Study, Eating Almonds Daily Could Improve Diabetes Risk Factors - Vimarsana News

According to a New Study, Eating Almonds Daily Could Improve Diabetes Risk Factors

A study reported that eating almonds daily for 12 weeks reduced insulin resistance, improved pancreatic function, and helped control blood glucose levels. What’s more, the almond treatment group achieved significant reductions in body weight, body mass index (BMI), and waist circumference over the intervention period and lowered their total cholesterol. The challenges of

Source: sakshi.com
At What Price Will Newer Anti-Diabetes Drugs Be Cost Effective? - Vimarsana News

At What Price Will Newer Anti-Diabetes Drugs Be Cost Effective?

In low- to middle-income countries, SGLT2 inhibitors could reduce diabetes complications at lower but feasible prices; they are cost effective at current prices in people with heart or kidney disease.